Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

S. Galiano Mejías, G. Carretero, C. Ferrandiz, F. Vanaclocha, E. Daudén, F. J. Gómez-García, E. Herrera-Ceballos, I. Belinchón-Romero, J. L. Sánchez-Carazo, J. L. López-Estebaranz, M. Alsina, M. Ferrán, R. Torrado, J. M. Carrascosa, R. Rivera, M. Llamas-Velasco, R. Jiménez-Puya, Mª V. Mendiola, D. Ruiz-Genao, M. A. DescalzoP. de la Cueva Dobao

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

© 2016 AEDV Background and objective We now have considerable experience in the use of biologic agents to treat psoriasis, but doubts about management arise in certain clinical settings. Surgery is one of them. Although treatment guidelines advise that biologics be suspended before major surgery, data about actual clinical practices and associated complications are lacking. We aimed to analyze current practice in the clinical management of these cases. Methods Retrospective study of cases in the Biobadaderm database. We analyzed the management of biologic therapy in patients with psoriasis who underwent surgical procedures. Results Forty-eight of the 2113 patients registered in Biobadaderm underwent surgery. The largest percentage of procedures (31%) involved skin lesions. Biologic treatment was interrupted in 42% of the cases. No postsurgical complications were significantly related to treatment interruption. Likewise we detected no associations between treatment interruption and other variables, such as sex, age, or duration or severity of psoriasis. Conclusion Continuity of biologic treatment and the risk of postsurgical complications were not associated in this study, although conclusions are limited by the small sample size.
Original languageEnglish
Pages (from-to)52-58
JournalActas Dermo-Sifiliograficas
Volume108
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Biologic agents
  • Psoriasis
  • Surgery
  • Systemic therapy
  • Treatment interruption

Fingerprint Dive into the research topics of 'Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry'. Together they form a unique fingerprint.

Cite this